The long-term goal of this research is to determine the molecular mechanisms underlying the signal transduction pathways in osteoblasts and to elucidate the physiological functions of Ca+ channels in bone.
The Specific Aims are to: 1) Test the hypothesis that total [3H]-1,25D3 binding is predicted quantitatively by VDR message, the RO displaces plasma membrane (or cytosolic) binding sites, whereas EO displaces nuclear labeling. Using receptor binding techniques with [3H]-1,25D3, the pharmacology and distribution of RO and EO (an agent which acts at the nVDR to stimulate transcription but is not effective at activation of Ca+ channels below 10 nM) will be quantitated and correlated in cells lines which express different levels of VDR message; 2) Determine whether message of nuclear receptors of other steroid hormones predict the steroid hormone potentiation of Ca+ channels. ROS 17/2.8 cells show potentiation of Ca+ currents with addition of 0.1 nM testosterone, but doses of up to 100 nM 17B estradiol cause minimal effects. The principal investigator proposes to test the hypothesis that transfection of the normal estrogen receptor into """"""""estrogen unresponsive"""""""" ROS 17/2.8 cells, will cause a rapid potentiation of Ca+ channels by low doses of 17B estradiol. The sensitivity of the non-genomic response will be quantitated to the level of expression of steroid receptor message; 3) Determine the Ca+ channel isoform in ROS 17/2.8 cells and mature rat bone which is associated with the response to steroid hormones. To answer which channel isoforms are present in mature rat bone or ROS cell cultures, oligonucleotides specific to the major L-type Ca+ channel isoforms, knockout technology will be used to specifically define which channel type is activated by steroid receptors. The steroid-activated Ca+ channel isoform will be cloned and expressed. Ca+ channels are involved in bone matrix production and bone resorption, and investigation of their pharmacology may yield new methods of drug treatment for bone disease.
|Li, Fangping; Wang, Wenwei; Gu, Ming et al. (2011) L-type calcium channel activity in osteoblast cells is regulated by the actin cytoskeleton independent of protein trafficking. J Bone Miner Metab 29:515-25|
|Silva, Ian V; Cebotaru, Valeriu; Wang, Hua et al. (2003) The ClC-5 knockout mouse model of Dent's disease has renal hypercalciuria and increased bone turnover. J Bone Miner Res 18:615-23|
|Zhao, Pei-Lin; Wang, Xi-Tao; Zhang, Xue-Mei et al. (2002) Tubular and cellular localization of the cardiac L-type calcium channel in rat kidney. Kidney Int 61:1393-406|
|Kadiyala, S; Nagaba, S; Takeuchi, K et al. (2001) Metabolites and analogs of 1alpha,25-dihydroxyvitamin D(3): evaluation of actions in bone. Steroids 66:347-55|
|Silva, I V; Blaisdell, C J; Guggino, S E et al. (2000) PTH regulates expression of ClC-5 chloride channel in the kidney. Am J Physiol Renal Physiol 278:F238-45|
|Wang, S S; Devuyst, O; Courtoy, P J et al. (2000) Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum Mol Genet 9:2937-45|
|Lajeunesse, D; Delalandre, A; Guggino, S E (2000) Thiazide diuretics affect osteocalcin production in human osteoblasts at the transcription level without affecting vitamin D3 receptors. J Bone Miner Res 15:894-901|
|Wang, X T; Nagaba, S; Nagaba, Y et al. (2000) Cardiac L-type calcium channel alpha 1-subunit is increased by cyclic adenosine monophosphate: messenger RNA and protein expression in intact bone. J Bone Miner Res 15:1275-85|
|Wang, X T; Nagaba, Y; Cross, H S et al. (2000) The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol 157:1549-62|
|Lajeunesse, D; Moreau, R; Hobbs, W et al. (1998) Influence of aluminum on the regulation of PTH- and 1,25(OH)2D3-dependent pathways in the rat osteosarcoma cell line ROS 17/2.8. J Bone Miner Res 13:962-9|
Showing the most recent 10 out of 12 publications